Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Foley

Showing results (71-80 of 127) with videos related to

Pageof 13
Sort By:
Biologics : Targets & Therapy|December 11, 2013
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionKavitha Damal, Emily Stoker, John F Foley
The Lancet. Neurology|February 21, 2023
Extended-interval dosing of natalizumab in NOVA - Authors' replyJohn F Foley, Nolan Campbell, George Kong
Journal of Managed Care Pharmacy : JMCP|February 7, 2013
Evidence for long-term use of intramuscular interferon beta-1a: an overview of relapse, disability, and MRI data from selected clinical trialsJohn F Foley, Kristine Zerkowski, Kavita V Nair
Journal of Managed Care Pharmacy : JMCP|February 7, 2013
Emerging methods for evaluating the effectiveness of intramuscular interferon beta-1a for relapsing-remitting multiple sclerosisJohn F Foley, Christopher J Barnes, Kavita V Nair
Current Treatment Options in Neurology|April 15, 2009
Monoclonal antibody treatments for multiple sclerosisJohn W Rose, John F Foley, Noel G Carlson
Circulation|August 16, 2006
Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathwayJana Barlic, Yuan Zhang, John F Foley, et al.
The Journal of Biological Chemistry|March 19, 2004
On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2Jeremy J Rose, John F Foley, Philip M Murphy, et al.
Multiple Sclerosis and Related Disorders|April 3, 2019
Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosingJohn F Foley, Susan Goelz, Tamara Hoyt, et al.
Journal of Biomedical Science|March 4, 2008
Cholesterol is obligatory for polarization and chemotaxis but not for endocytosis and associated signaling from chemoattractant receptors in human neutrophilsJeremy J Rose, John F Foley, Ling Yi, et al.
Science Signaling|February 14, 2008
2007: signaling breakthroughs of the yearElizabeth M Adler, John F Foley, Nancy R Gough, et al.
Pageof 13

Showing results (71-80 of 127) with videos related to

Sort By:
Pageof 13
Biologics : Targets & Therapy|December 11, 2013
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionKavitha Damal, Emily Stoker, John F Foley
The Lancet. Neurology|February 21, 2023
Extended-interval dosing of natalizumab in NOVA - Authors' replyJohn F Foley, Nolan Campbell, George Kong
Journal of Managed Care Pharmacy : JMCP|February 7, 2013
Evidence for long-term use of intramuscular interferon beta-1a: an overview of relapse, disability, and MRI data from selected clinical trialsJohn F Foley, Kristine Zerkowski, Kavita V Nair
Journal of Managed Care Pharmacy : JMCP|February 7, 2013
Emerging methods for evaluating the effectiveness of intramuscular interferon beta-1a for relapsing-remitting multiple sclerosisJohn F Foley, Christopher J Barnes, Kavita V Nair
Current Treatment Options in Neurology|April 15, 2009
Monoclonal antibody treatments for multiple sclerosisJohn W Rose, John F Foley, Noel G Carlson
Circulation|August 16, 2006
Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathwayJana Barlic, Yuan Zhang, John F Foley, et al.
The Journal of Biological Chemistry|March 19, 2004
On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2Jeremy J Rose, John F Foley, Philip M Murphy, et al.
Multiple Sclerosis and Related Disorders|April 3, 2019
Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosingJohn F Foley, Susan Goelz, Tamara Hoyt, et al.
Journal of Biomedical Science|March 4, 2008
Cholesterol is obligatory for polarization and chemotaxis but not for endocytosis and associated signaling from chemoattractant receptors in human neutrophilsJeremy J Rose, John F Foley, Ling Yi, et al.
Science Signaling|February 14, 2008
2007: signaling breakthroughs of the yearElizabeth M Adler, John F Foley, Nancy R Gough, et al.
Pageof 13